A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

Basic Principles of Platelet Biology and Clinical Implications

(2010) Dominick J. Angiolillo et al.   CIRCULATION JOURNAL

A Double-Blind, Randomized Study on Prevention and Existence of a Rebound Phenomenon of Platelets After Cessation of Clopidogrel Treatment

(2010) Dirk Sibbing et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

(2009) Christoph Varenhorst et al.   AMERICAN HEART JOURNAL

Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions

(2009) D. J. Angiolillo   DIABETES CARE

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

(2008) Stephen D. Wiviott et al.   CIRCULATION

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study

(2008) D. J. Angiolillo et al.   EUROPEAN HEART JOURNAL

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation

(2008) Matthew J. Price et al.   EUROPEAN HEART JOURNAL

Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome

(2008) P. Michael Ho   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance

(2008) Laurent Bonello et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo

(2008) David Erlinge et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition on Standard Dose Treatment

(2007) Dominick J. Angiolillo et al.   AMERICAN JOURNAL OF CARDIOLOGY